ATE348152T1 - Verfahren zum screening von diabetes- heilverfahren - Google Patents

Verfahren zum screening von diabetes- heilverfahren

Info

Publication number
ATE348152T1
ATE348152T1 AT01998193T AT01998193T ATE348152T1 AT E348152 T1 ATE348152 T1 AT E348152T1 AT 01998193 T AT01998193 T AT 01998193T AT 01998193 T AT01998193 T AT 01998193T AT E348152 T1 ATE348152 T1 AT E348152T1
Authority
AT
Austria
Prior art keywords
screening diabetes
cure
diabetes cure
screening
cell
Prior art date
Application number
AT01998193T
Other languages
English (en)
Inventor
Takahide Ohishi
Jun Takasaki
Mitsuyuki Matsumoto
Chou-Ku
Tetsu Saito
Masazumi Kamohara
Takatoshi Soga
Shigeru Yoshida
Yoshitaka Ueda
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26605096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE348152(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE348152T1 publication Critical patent/ATE348152T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01998193T 2000-12-01 2001-11-30 Verfahren zum screening von diabetes- heilverfahren ATE348152T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367349 2000-12-01
JP2001243841 2001-08-10

Publications (1)

Publication Number Publication Date
ATE348152T1 true ATE348152T1 (de) 2007-01-15

Family

ID=26605096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998193T ATE348152T1 (de) 2000-12-01 2001-11-30 Verfahren zum screening von diabetes- heilverfahren

Country Status (8)

Country Link
US (3) US20030180813A1 (de)
EP (2) EP1338651B9 (de)
JP (1) JP3438186B2 (de)
AT (1) ATE348152T1 (de)
AU (1) AU2002218509A1 (de)
DE (1) DE60125227T2 (de)
ES (1) ES2280435T3 (de)
WO (1) WO2002044362A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US20030125539A1 (en) * 1999-02-22 2003-07-03 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP2002130117A (ja) * 2000-10-18 2002-05-09 Mikuni Corp 電磁駆動型プランジャポンプ
ATE348152T1 (de) * 2000-12-01 2007-01-15 Astellas Pharma Inc Verfahren zum screening von diabetes- heilverfahren
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US20050191612A1 (en) * 2002-09-11 2005-09-01 Takahide Ohishi Method of screening insulin content enhancer
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
JPWO2004084944A1 (ja) * 2003-03-25 2006-06-29 住友製薬株式会社 新規血糖調節薬及びそのスクリーニング方法
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005009469A1 (ja) * 2003-07-28 2005-02-03 Sumitomo Pharmaceuticals Co., Ltd. 新規血糖調節薬及びそのスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
ES2354390T3 (es) 2006-04-11 2011-03-14 Arena Pharmaceuticals, Inc. Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo.
MX2009011358A (es) * 2007-04-20 2009-11-05 Schering Corp Derivados de pirimidinona y metodos para su uso.
EP2148870A1 (de) * 2007-04-20 2010-02-03 Schering Corporation Pyrimidinonderivate und verfahren zu deren anwendung
CN101668759A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,5]-双环gpr119g蛋白-偶合受体激动剂
ES2388967T3 (es) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
TW200904440A (en) 2007-07-17 2009-02-01 Bristol Myers Squibb Co Method for modulating GPR119 G protein-coupled receptor and selected compounds
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
EP2146210A1 (de) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
US20110065671A1 (en) 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010009208A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010075271A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
AU2009330206A1 (en) 2008-12-23 2011-07-07 Merck Sharp & Dohme Corp. Pyrimidine derivatives as GPCR modttlators for use in the treatment of obesity and diabetes
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
WO2010114957A1 (en) 2009-04-03 2010-10-07 Schering Corporation Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
EP2547339A1 (de) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Kombination eines gpr119-agonisten und des dpp-iv-hemmers linagliptin zur verwendung bei der behandlung von diabetes und zugehöriger erkrankungen
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
EA201270755A1 (ru) 2010-04-08 2013-03-29 Бристол-Майерс Сквибб Компани Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
WO2012115640A1 (en) * 2011-02-23 2012-08-30 Elona Biotechnologies Liquid insulin- containing compositions and methods of making the same
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EP3197473B1 (de) * 2014-09-24 2021-03-31 University Of Oregon Proteine zur erhöhung der anzahl an pankreatischen beta-zellen und verfahren zur verwendung
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL260444A (de) 1960-12-05
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose
IT1256191B (it) * 1992-12-03 1995-11-29 Impiego di lisolecitine nel trattamento della impotenza maschile e dell'alopecia e relative composizioni atte a tale impiego.
WO2000022131A2 (en) 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
DK1133559T3 (da) 1998-11-20 2006-04-10 Arena Pharm Inc Human-G-protein-koblet orphan receptor RUP3
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
CA2360687A1 (en) * 1999-01-29 2000-08-03 Karl H. Beyer, Jr. (Deceased) Composition and method for treating diabetes
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
GB9923177D0 (en) * 1999-09-30 1999-12-01 Pfizer Ltd Novel polypeptide
JP2003513629A (ja) * 1999-11-03 2003-04-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 新規なｇｐｃｒ＿ｋｄ５ポリペプチドおよびそのｄｎａ配列
CA2388865A1 (en) 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Novel g protein-coupled receptors
EP1235860A2 (de) 1999-12-10 2002-09-04 Incyte Genomics, Inc. G-protein gekoppelte rezeptoren
PT1287133E (pt) * 2000-05-18 2007-03-30 Bayer Healthcare Ag Regulação do receptor acoplado à proteína g tipo dopamina humano
US20040067499A1 (en) 2000-08-04 2004-04-08 Tatsuya Haga Novel g protein-coupled receptor
ATE348152T1 (de) 2000-12-01 2007-01-15 Astellas Pharma Inc Verfahren zum screening von diabetes- heilverfahren
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
EP1364013A1 (de) 2001-02-14 2003-11-26 PHARMACIA & UPJOHN COMPANY G-protein gekoppelter rezeptor

Also Published As

Publication number Publication date
EP1338651A4 (de) 2005-04-27
EP1338651A1 (de) 2003-08-27
DE60125227D1 (de) 2007-01-25
EP1338651B9 (de) 2007-05-09
EP1770159A1 (de) 2007-04-04
US20050136484A1 (en) 2005-06-23
EP1338651B1 (de) 2006-12-13
WO2002044362A1 (en) 2002-06-06
US20030180813A1 (en) 2003-09-25
JPWO2002044362A1 (ja) 2004-04-02
US20100144677A1 (en) 2010-06-10
JP3438186B2 (ja) 2003-08-18
ES2280435T3 (es) 2007-09-16
US7662775B2 (en) 2010-02-16
AU2002218509A1 (en) 2002-06-11
DE60125227T2 (de) 2007-09-20

Similar Documents

Publication Publication Date Title
DE60125227D1 (de) Verfahren zum screening von diabetes-heilverfahren
GB2217717B (en) Process for the production of porous membranes,the membranes produced thereby and their use as supporting matrices in test strips
ATE110415T1 (de) Verbessertes verfahren und apparat, um biologische substanzen in lebenden zellen einzuführen.
DE69229174D1 (de) Verwendung von haloalkylderivaten von reportermolekülen zur analyse der metabolischen aktivität in zellen
FI904534A0 (fi) Foerfarande och anordning foer amperometrisk diagnosanalys.
DE60029209D1 (de) Vorrichtung und verfahren zur einbringung von substanzen in eine zelle durch elektroporation
ATE418729T1 (de) Verfahren zur charakterisierung von biomolekülen mittels resultat-gesteuerter strategie
CH399779A (fr) Indicateur et son utilisation pour doser les substances dans les liquides biologiques
DE69427255D1 (de) Herstellung von Tetrazolium-Salz-Indikatoren enthaltenden diagnostischen Teststreifen
DE3788388D1 (de) Verfahren zur Herstellung eines REFETs oder eines CHEMFETs, sowie deren Herstellung.
WO2002042500A3 (en) Apparatus and method for electrophoretic microspot concentration
DK0681590T3 (da) Antikoagulerende sammensætning
DE602005025401D1 (de) Hes verfahren unter verwendung davon
DE60236530D1 (de) Verfahren zur vorbehandlung von proben zur bestimmung von verzuckerten aminen, sowie verfahren zur bestimmung von verzuckerten aminen
AU2003302816A1 (en) Method for manufacturing tool for analysis
ATE483975T1 (de) Behälter und kits zur bestimmung von zellfunktionen und verfahren zu deren bestimmung
ATE534903T1 (de) Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse
SE437303B (sv) Forfarande for on-line-metning av koncentrationen av en analyt i en behallare, samt apparat for genomforande av forfarandet
ES2089132T3 (es) Analisis de pelo.
DE69715034D1 (de) Verfahren zur herstellung von dem anaphase-fördernden komplex
CA2004068A1 (en) Hair analysis method
Tsuda et al. A new type of N-nitrosamino acid, N-nitroso-L-thioproline and N-nitroso-L-methylthioprolines, found in human urine as major N-nitroso compounds
Esaka et al. Separation of amino acid—oxazole derivatives of the redox coenzyme pyrroloquinoline quinone by capillary zone electrophoresis
ATE440278T1 (de) Verfahren und vorrichtung zur charakterisierung von osi-material
IS3331A7 (is) Aðferð til að nota skönnunarsmásjá og myndgreini til efnagreingingar, með því að mæla meðal sætistölu frumefna í efnafösum, sem innihalda létt frumefni.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1338651

Country of ref document: EP